Editorial Material
Hematology
Peter W. M. Johnson
Summary: The study shows that treating relapsed or refractory HL with PD-1 antibody nivolumab has a high response rate, making it an attractive option for second-line therapy.
Editorial Material
Oncology
Cedric Rossi, Rene-Olivier Casasnovas
Summary: Novel targeted approaches have significantly improved the prognosis of patients with relapsed/refractory Hodgkin lymphoma, especially with the use of inhibitors like Nivolumab and pembrolizumab.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Deepa Jagadeesh, Steve Horwitz, Nancy L. Bartlett, Youn Kim, Eric Jacobsen, Madeleine Duvic, Meredith Little, William Trepicchio, Keenan Fenton, Matthew Onsum, Julie Lisano, Ranjana Advani
Summary: This article examines the relationship between CD30 expression level and clinical response to brentuximab vedotin. The analysis showed that CD30 expression alone cannot predict the clinical benefit of brentuximab vedotin.
Review
Hematology
Maliha Khan, Fredrick Hagemeister, Michael Wang, Sairah Ahmed
Summary: This article discusses the classification of Hodgkin lymphoma, the biology of classical Hodgkin lymphoma (cHL), and the available treatment options for relapsed cHL. Brentuximab vedotin and immune checkpoint inhibitors have shown efficacy in the treatment of cHL, and chimeric antigen receptor T-cell therapy is being explored as a potential treatment option.
Article
Hematology
Sanjal H. Desai, Michael A. Spinner, Kevin David, Veronika Bachanova, Gaurav Goyal, Brad Kahl, Kathleen Dorritie, Jacques Azzi, Vaishalee P. Kenkre, Sally Arai, Cheryl Chang, Brendon Fusco, Nuttavut Sumransub, Haris Hatic, Raya Saba, Uroosa Ibrahim, Elyse Harris, Harsh Shah, Jacob Murphy, Stephen Ansell, Deepa Jagadish, Victor Orellana-noia, Catherine Diefenbach, Siddharth Iyenger, K. C. Rappazzo, Rahul Mishra, Yun Choi, Grzegorz S. Nowakowski, Ranjana H. Advani, Ivana N. Micallef
Summary: This multicenter retrospective study found that salvage therapies with checkpoint inhibitor (CPI)-based regimens had superior event-free survival (EFS) and progression-free survival (PFS) compared to conventional chemotherapy and other salvage regimens, supporting the use of CPI-based regimens in relapsed/refractory transplant-eligible classic Hodgkin lymphoma (R/R cHL) in the pre-autologous stem cell transplant (ASCT) setting.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Review
Oncology
Huimin Ma, Xin Li, Meng Lin, Kebing Lv, Mingzhi Zhang, Xiaolong Wu
Summary: The current standard treatment for relapsed or refractory HL is salvage chemotherapy followed by ASCT, but it may not be successful for all patients. New treatment options including targeted therapy and immunotherapy, such as BV and anti-PD-1 antibodies, have shown effectiveness in treating these patients. BV and anti-PD-1 antibodies can be used alone or in combination with other chemotherapy regimens for rescue, consolidation, and second-line treatment of R/R HL.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Review
Oncology
Walter Hanel, Alex F. Herrera, Narendranath Epperla
Summary: The treatment landscape of classical Hodgkin lymphoma has significantly changed in the past 20 years, with improvements in patient management and increased complexity in treatment approaches. By incorporating new drugs and adjusting treatment sequences, long-term remission can be achieved, and treatment advancements are expected to continue with ongoing clinical trials.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Yang Wu, Dan Chen, Ya Lu, Shu-Chen Dong, Rong Ma, Wei-yan Tang, Jian-qiu Wu, Ji-Feng Feng, Jian-Zhong Wu
Summary: The study demonstrated an effective CAR-T cell treatment for CD30-positive PTCL tumors by using CD30 CAR T cells to suppress tumor growth.
CANCER GENE THERAPY
(2022)
Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Article
Oncology
Fulvio Massaro, Nathalie Meuleman, Dominique Bron, Marie Vercruyssen, Marie Maerevoet
Summary: This retrospective study evaluated the efficacy of a combination of brentuximab vedotin and pembrolizumab as a bridge treatment to autologous stem cell transplantation (ASCT) in relapsed/refractory Hodgkin lymphoma (HL) patients. The results showed that this combination therapy is highly effective for high-risk patients.
Review
Biochemistry & Molecular Biology
Theodoros P. Vassilakopoulos, Athanasios Liaskas, Patricio Pereyra, Panayiotis Panayiotidis, Maria K. Angelopoulou, Andrea Gallamini
Summary: The long-term survival of HL patients is excellent with current standard of care, including combined-modality schedules and treatment intensity adaptation. However, a significant number of patients still experience primary refractory or relapse. Novel immunotherapeutic agents, such as BV and CPI, have shown outstanding efficacy in relapsed/refractory settings. Adding these agents in frontline treatment may further improve disease control and reduce the need for cytotoxic drugs. The results of ongoing phase 3 trials incorporating anti-PD-1 in this setting will provide more insights.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Yujie Zhang, Zhichao Xing, Li Mi, Zhihui Li, Jingqiang Zhu, Tao Wei, Wenshuang Wu
Summary: Classical Hodgkin lymphoma, the most common type of HL, mainly affects people in certain age groups. A significant proportion of patients with refractory or relapsed cHL do not respond well to treatment. Exploring new predictive strategies and treatment measures may help improve the cure rate for these patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O'Shea, Leo I. Gordon, Jane N. Winter
Summary: Brief pembrolizumab monotherapy followed by AVD is highly effective and safe for patients with newly diagnosed classical Hodgkin lymphoma, including those with bulky disease.
Review
Hematology
M. Veyri, J. P. Spano, F. Le Bras, A. G. Marcelin, E. Todesco
Summary: CD30 is a transmembrane protein expressed on a subset of activated T and B lymphocytes as well as lymphoid neoplasms. It is a promising therapeutic target due to its high levels in tumors and low levels in healthy tissues. Various therapeutic strategies have been developed, including monoclonal antibodies, bispecific antibodies, and cell and gene therapies such as anti-CD30 CAR-T cells. This review provides an overview of the biology of CD30 and describes the current anti-CD30 therapies.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Luciana Vinti, Daria Pagliara, Salvatore Buffardi, Valentina Di Ruscio, Francesca Stocchi, Elena Mariggio, Rosanna Parasole, Antonia Di Matteo, Fara Petruzziello, Valeria Paganelli, Rita De Vito, Francesca Del Bufalo, Luisa Strocchio, Franco Locatelli
Summary: Combination therapy with brentuximab vedotin and bendamustine may be a suitable salvage therapy for children and young adults with Hodgkin's lymphoma, showing a high overall response rate and 3-year survival rate.
PEDIATRIC BLOOD & CANCER
(2022)